Jean-Pierre Bizzari, M.D., has served as a member of ADC Therapeutics' board of directors since June 2022. He is a member of the scientific advisory board of France's National Cancer Institute and a board member of the European Organisation for Research and Treatment of Cancer. From 2008 to 2015 he served as Executive Vice President, Group Head of Clinical Development Oncology at Celgene, and earlier held senior clinical development positions at Sanofi, Aventis and Rhone-Poulenc. He also serves on the board of APREA Therapeutics and previously served on the boards of Transgene, Onxeo, Compugen and Halozyme Therapeutics. Dr. Bizzari holds an M.D. from Nice Medical School.